HONG KONG – With a nod to proceed from the Korea Food and Drug Administration, Seoul-based Kainos Medicine Inc. is taking its Parkinson's disease candidate, KR-33493, into the clinic with the belief that it represents a fundamental improvement in the battle against the disease as the first to potentially alter Parkinson's rather than just addressing the symptoms.
HONG KONG – With a nod to proceed from the Korea Food and Drug Administration, Seoul-based Kainos Medicine Inc. is taking its Parkinson's disease candidate, KR-33493, into the clinic with the belief that it represents a fundamental improvement in the battle against the disease as the first to potentially alter Parkinson's rather than just addressing the symptoms.
HONG KONG – Marking another step in its path to profitability, South Korea’s Samsung Bioepis Co. Ltd. reported a first approval in its home market for a biosimilar – Brenzys – based on Amgen Inc.’s blockbuster Enbrel (etanercept) to treat arthritis.
HONG KONG – Indonesia, home to the largest Muslim population in the world, wants to lead the way in developing a simpler halal certification pathway for pharmaceutical and biomedical products. Some observers worry, however, that full implementation of laws that completely marry the needs of Muslim Sharia Law and those of traditional drug approval and certification pathways may prove impossible.
HONG KONG – Marking another step in its path to profitability, South Korea's Samsung Bioepis Co. Ltd. reported a first approval in its home market for a biosimilar – Brenzys – based on Amgen Inc.'s blockbuster Enbrel (etanercept) to treat arthritis.
HONG KONG – Regulators around the world – beyond Muslim countries in Asia and the Middle East – are increasingly exploring the impact of Sharia Law on the health care markets they oversee.
